IN2014DN03325A - - Google Patents
Info
- Publication number
- IN2014DN03325A IN2014DN03325A IN3325DEN2014A IN2014DN03325A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A IN 3325DEN2014 A IN3325DEN2014 A IN 3325DEN2014A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A
- Authority
- IN
- India
- Prior art keywords
- compound
- directed
- composition
- sulphur
- selene
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 239000005864 Sulphur Substances 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical group NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 abstract 1
- 241000791876 Selene Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 125000000962 organic group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161543510P | 2011-10-05 | 2011-10-05 | |
| NL2007536A NL2007536C2 (en) | 2011-10-05 | 2011-10-05 | Adjuvant compound. |
| US201261615566P | 2012-03-26 | 2012-03-26 | |
| PCT/NL2012/050694 WO2013051936A1 (en) | 2011-10-05 | 2012-10-04 | Adjuvant compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN03325A true IN2014DN03325A (instruction) | 2015-06-26 |
Family
ID=48043964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3325DEN2014 IN2014DN03325A (instruction) | 2011-10-05 | 2012-10-04 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9314521B2 (instruction) |
| EP (1) | EP2763697B9 (instruction) |
| JP (1) | JP6099210B2 (instruction) |
| KR (1) | KR102053699B1 (instruction) |
| CN (1) | CN104244976B (instruction) |
| AU (1) | AU2012319265B2 (instruction) |
| BR (1) | BR112014008214B1 (instruction) |
| CA (1) | CA2886631C (instruction) |
| EA (1) | EA030741B1 (instruction) |
| ES (1) | ES2952644T3 (instruction) |
| IL (1) | IL231951B (instruction) |
| IN (1) | IN2014DN03325A (instruction) |
| MX (1) | MX356028B (instruction) |
| NL (1) | NL2007536C2 (instruction) |
| SG (1) | SG11201401291XA (instruction) |
| WO (1) | WO2013051936A1 (instruction) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| EP2976325B1 (en) | 2013-03-21 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Synthesis of cyclic imide containing peptide products |
| US10576144B2 (en) | 2013-06-28 | 2020-03-03 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| KR102569204B1 (ko) | 2014-06-02 | 2023-08-22 | 아이에스에이 파마슈티컬즈 비.브이. | B형 간염 바이러스 감염에 대한 치료 백신접종을 위한 합성 롱 펩티드(slp) |
| RU2017126206A (ru) | 2014-12-23 | 2019-01-25 | Маргарет Анне БРИМБЛЕ | Аминокислотные и пептидные конъюгаты и направления их использования |
| IL298653A (en) | 2015-12-11 | 2023-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201521894D0 (en) * | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| CN108884020A (zh) | 2016-02-26 | 2018-11-23 | 奥克兰联合服务有限公司 | 氨基酸及肽共轭物以及共轭过程 |
| EP3552623A1 (en) | 2016-06-20 | 2019-10-16 | ISA Pharmaceuticals B.V | Formulation of a peptide vaccine |
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| CN110650750A (zh) | 2017-04-04 | 2020-01-03 | 阿维迪科技公司 | 基于肽的疫苗、其制造方法及其用于诱导免疫应答的用途 |
| WO2019122050A1 (en) | 2017-12-22 | 2019-06-27 | Isa Pharmaceuticals B.V. | Methods of immunization |
| KR20220004634A (ko) | 2019-03-15 | 2022-01-11 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Her2를 표적으로 하는 면역접합체 |
| KR20220143812A (ko) | 2019-12-07 | 2022-10-25 | 아이에스에이 파마슈티컬즈 비.브이. | B형 간염 바이러스와 관련된 질병의 치료 |
| US20230087422A1 (en) | 2020-02-07 | 2023-03-23 | Isa Pharmaceuticals B.V. | Treatment of hpv-related diseases |
| WO2021214297A1 (en) | 2020-04-23 | 2021-10-28 | Isa Pharmaceuticals B.V. | Immunization against sars-cov-related diseases |
| KR20240029765A (ko) | 2021-07-12 | 2024-03-06 | 아이에스에이 파마슈티컬즈 비.브이. | 복잡한 혼합물에서의 개선된 물질 정량화 |
| WO2024068636A1 (en) | 2022-09-27 | 2024-04-04 | Isa Pharmaceuticals B.V. | Adjuvanted immunogenic peptides for intradermal administration |
| EP4601685A1 (en) | 2022-10-13 | 2025-08-20 | Isabella Pharma B.V. | Modified long peptides suitable for use in immunisation |
| WO2024149888A1 (en) | 2023-01-12 | 2024-07-18 | Isa Pharmaceuticals B.V. | Improved lipopeptide quantification |
| WO2025008085A1 (en) | 2023-07-05 | 2025-01-09 | Isa Pharmaceuticals B.V. | Immunotherapy for the treatment of prame-expressing cancers |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3485094D1 (de) * | 1983-01-25 | 1991-10-31 | Ciba Geigy Ag | Neue peptidderivate. |
| US6024964A (en) * | 1985-06-24 | 2000-02-15 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| DE3937412A1 (de) * | 1989-11-10 | 1991-05-16 | Hoechst Ag | Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten |
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| US6686447B1 (en) | 1999-06-30 | 2004-02-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6504010B1 (en) | 1999-06-30 | 2003-01-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| CN1367829A (zh) | 1999-06-30 | 2002-09-04 | 科里克萨有限公司 | 用于肺癌治疗和诊断的组合物和方法 |
| US20030211510A1 (en) | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| NL1012739C2 (nl) | 1999-07-29 | 2001-01-30 | Maasland Nv | Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer. |
| NZ526326A (en) | 2000-12-08 | 2006-09-29 | Academisch Ziekenhuis Leiden | A CTL epitope petide of 22-45 amino acid residues for inducing and/or enhancing an antigen-specific T-cell response |
| MXNL04000056A (es) | 2004-06-30 | 2006-01-11 | Mario Alberto Aguilera Rico | Sistema de construccion terra acero. |
| JP2010500407A (ja) * | 2006-08-14 | 2010-01-07 | サイモン・エル・エル・シー | Ｈｉｖ−１の複数の株及びサブタイプを治療及び予防するための組成物及び方法 |
| CA2996732C (en) | 2007-03-26 | 2020-10-27 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Prame derived peptides and immunogenic compositions comprising these |
| CN111686244A (zh) | 2007-05-31 | 2020-09-22 | 莱顿教学医院 | 侵润宫颈恶性肿瘤的t细胞所靶向的用于疫苗的hpv表位 |
| ES2406077T3 (es) | 2007-05-31 | 2013-06-05 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Vacuna de péptido p53 |
| KR100900837B1 (ko) * | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 |
| WO2011119759A1 (en) * | 2010-03-23 | 2011-09-29 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
-
2011
- 2011-10-05 NL NL2007536A patent/NL2007536C2/en active
-
2012
- 2012-10-04 MX MX2014004114A patent/MX356028B/es active IP Right Grant
- 2012-10-04 IN IN3325DEN2014 patent/IN2014DN03325A/en unknown
- 2012-10-04 CA CA2886631A patent/CA2886631C/en active Active
- 2012-10-04 ES ES12780309T patent/ES2952644T3/es active Active
- 2012-10-04 EA EA201490709A patent/EA030741B1/ru not_active IP Right Cessation
- 2012-10-04 AU AU2012319265A patent/AU2012319265B2/en active Active
- 2012-10-04 US US14/349,652 patent/US9314521B2/en active Active
- 2012-10-04 BR BR112014008214-6A patent/BR112014008214B1/pt active IP Right Grant
- 2012-10-04 SG SG11201401291XA patent/SG11201401291XA/en unknown
- 2012-10-04 CN CN201280059738.4A patent/CN104244976B/zh active Active
- 2012-10-04 JP JP2014534504A patent/JP6099210B2/ja active Active
- 2012-10-04 EP EP12780309.6A patent/EP2763697B9/en active Active
- 2012-10-04 KR KR1020147012025A patent/KR102053699B1/ko active Active
- 2012-10-04 WO PCT/NL2012/050694 patent/WO2013051936A1/en active Application Filing
-
2014
- 2014-04-03 IL IL231951A patent/IL231951B/en active IP Right Grant
-
2016
- 2016-03-07 US US15/062,589 patent/US9770506B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140093673A (ko) | 2014-07-28 |
| EA030741B1 (ru) | 2018-09-28 |
| IL231951A0 (en) | 2014-05-28 |
| EP2763697B1 (en) | 2023-06-07 |
| NL2007536C2 (en) | 2013-04-08 |
| EA201490709A1 (ru) | 2014-09-30 |
| SG11201401291XA (en) | 2014-05-29 |
| MX356028B (es) | 2018-05-09 |
| CN104244976B (zh) | 2017-05-31 |
| MX2014004114A (es) | 2014-10-17 |
| JP6099210B2 (ja) | 2017-03-22 |
| WO2013051936A9 (en) | 2013-09-12 |
| IL231951B (en) | 2019-08-29 |
| BR112014008214A2 (pt) | 2017-06-13 |
| EP2763697B8 (en) | 2023-07-12 |
| US9770506B2 (en) | 2017-09-26 |
| ES2952644T3 (es) | 2023-11-02 |
| CA2886631A1 (en) | 2013-04-11 |
| EP2763697B9 (en) | 2023-10-04 |
| US20160250325A1 (en) | 2016-09-01 |
| AU2012319265B2 (en) | 2016-10-13 |
| EP2763697A1 (en) | 2014-08-13 |
| BR112014008214B1 (pt) | 2022-07-05 |
| EP2763697C0 (en) | 2023-06-07 |
| AU2012319265A1 (en) | 2014-05-22 |
| US9314521B2 (en) | 2016-04-19 |
| CN104244976A (zh) | 2014-12-24 |
| NZ623869A (en) | 2015-11-27 |
| WO2013051936A1 (en) | 2013-04-11 |
| CA2886631C (en) | 2019-06-11 |
| US20150104473A1 (en) | 2015-04-16 |
| JP2014530808A (ja) | 2014-11-20 |
| KR102053699B1 (ko) | 2019-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN03325A (instruction) | ||
| WO2016077464A8 (en) | Amino acid derivatives and their uses | |
| MY200083A (en) | Cyclic dinucleotide compounds | |
| BR112012007411A2 (pt) | composto, processo para sua preparação e composição farmacêutica contendo o mesmo | |
| TR201900128T4 (tr) | Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller. | |
| MX2010007587A (es) | Compuestos que comprenden un grupo ciclobutoxi. | |
| MY159252A (en) | Process for the preparation of dopo-derived compounds and compositions thereof | |
| MX2012002502A (es) | Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos. | |
| BR112013020996A8 (pt) | derivados aminobutíricos substituídos como inibidores de neprilisina | |
| MY150596A (en) | Hsp90 inhibitors | |
| PH12012502352A1 (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
| JO2910B1 (en) | Organic compounds | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| MX2011007952A (es) | Tricianoboratos novedosos. | |
| MX2013000295A (es) | Procedimiento de preparacion de un inhibidor especifico de la trombina. | |
| MX352607B (es) | Proceso para la preparacion de benzoxaboroles. | |
| BR112013001132A2 (pt) | processo para preparação de compostos antivirais | |
| PH12013500694A1 (en) | Process for manufacturing dihydropteridinones and intermediates thereof | |
| MY167638A (en) | Treatment composition for textile goods | |
| WO2009137444A3 (en) | Cure accelerators for anaerobic curable compositions | |
| NZ704155A (en) | Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof | |
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| MX2013003387A (es) | Proceso para preparacion de producto de reaccion de urea ciclica y de aldehido multifuncional. | |
| UY32975A (es) | Derivados de aminopiridina | |
| BR112013024361A2 (pt) | novos compostos de azaspirodecanona como inibidores de hsl |